Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25897253
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Clin+Cosmet+Investig+Dermatol
2015 ; 8
(ä): 159-77
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Update on the management of rosacea
#MMPMID25897253
Weinkle AP
; Doktor V
; Emer J
Clin Cosmet Investig Dermatol
2015[]; 8
(ä): 159-77
PMID25897253
show ga
Refining diagnostic criteria has identified key characteristics differentiating
rosacea, a chronic skin disorder, from other common cutaneous inflammatory
conditions. The current classification system developed by the National Rosacea
Society Expert Committee consists of erythematotelangiectatic, papulopustular,
phymatous, and ocular subtypes. Each subtype stands as a unique entity among a
spectrum, with characteristic symptoms and physical findings, along with an
intricate pathophysiology. The main treatment modalities for rosacea include
topical, systemic, laser, and light therapies. Topical brimonidine tartrate gel
and calcineurin inhibitors are at the forefront of topical therapies, alone or in
combination with traditional therapies such as topical metronidazole or azelaic
acid and oral tetracyclines or isotretinoin. Vascular laser and intense pulsed
light therapies are beneficial for the erythema and telangiectasia, as well as
the symptoms (itching, burning, pain, stinging, swelling) of rosacea. Injectable
botulinum toxin, topical ivermectin, and microsecond long-pulsed
neodymium-yttrium aluminum garnet laser are emerging therapies that may prove to
be extremely beneficial in the future. Once a debilitating disorder, rosacea has
become a well known and manageable entity in the setting of numerous emerging
therapeutic options. Herein, we describe the treatments currently available and
give our opinions regarding emerging and combination therapies.
free
free
free
